Zimmer Biomet Holdings, Inc. (ZBH)
- Previous Close
92.27 - Open
92.85 - Bid 94.19 x 800
- Ask 94.23 x 1000
- Day's Range
92.39 - 94.45 - 52 Week Range
89.92 - 122.25 - Volume
2,125,885 - Avg. Volume
2,164,531 - Market Cap (intraday)
18.617B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
20.91 - EPS (TTM)
4.50 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield 0.96 (1.04%)
- Ex-Dividend Date Mar 31, 2025
- 1y Target Est
109.16
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
www.zimmerbiomet.comRecent News: ZBH
View More
Performance Overview: ZBH
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZBH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZBH
View MoreValuation Measures
Market Cap
18.26B
Enterprise Value
24.05B
Trailing P/E
20.50
Forward P/E
11.22
PEG Ratio (5yr expected)
1.14
Price/Sales (ttm)
2.42
Price/Book (mrq)
1.47
Enterprise Value/Revenue
3.12
Enterprise Value/EBITDA
10.47
Financial Highlights
Profitability and Income Statement
Profit Margin
11.86%
Return on Assets (ttm)
4.42%
Return on Equity (ttm)
7.32%
Revenue (ttm)
7.7B
Net Income Avi to Common (ttm)
913.4M
Diluted EPS (ttm)
4.50
Balance Sheet and Cash Flow
Total Cash (mrq)
1.38B
Total Debt/Equity (mrq)
59.06%
Levered Free Cash Flow (ttm)
1.32B
Research Analysis: ZBH
View MoreResearch Reports: ZBH
View MoreZimmer Biomet Earnings: Weakness in US Knees Disappoints, Lowering Our Fair Value Estimate
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
RatingPrice TargetMedical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
RatingPrice TargetMedical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
RatingPrice TargetProduct launches and M&A to drive 2025 growth
Based in Warsaw, Indiana, Zimmer Biomet is the nation's largest pure-play maker of orthopedic devices. The current company arose from the 2015 merger of Zimmer and Biomet, both of which were headquartered in Warsaw, Indiana. The company designs, develops, and manufactures reconstructive orthopedic implants, sports injury repair and trauma products, and related orthopedic surgical products. Its primary customers include musculoskeletal surgeons, neurosurgeons, hospitals, distributors, and, in their capacity as agents, healthcare purchasing organizations or buying groups. ZBH shares are a component of the S&P 500.
RatingPrice Target